Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Nav1.7 antagonists
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (5) , 2052-2062
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent PainJournal of Medicinal Chemistry, 2011
- Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated GlaucomaJournal of Medicinal Chemistry, 2009
- Voltage-gated sodium channels in pain states: Role in pathophysiology and targets for treatmentBrain Research Reviews, 2009
- Novel 2,3-Dihydro-1,4-Benzoxazines as Potent and Orally Bioavailable Inhibitors of Tumor-Driven AngiogenesisJournal of Medicinal Chemistry, 2008
- Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disordersJournal of Clinical Investigation, 2007
- From genes to pain: Nav1.7 and human pain disordersTrends in Neurosciences, 2007
- A stop codon mutation in SCN9A causes lack of pain sensationHuman Molecular Genetics, 2007
- SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and PhenotypesNeuron, 2006
- Structure−Activity Relationship of Heterobase-Modified 2‘-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA ReplicationJournal of Medicinal Chemistry, 2004
- Hereditary erythermalgia and acquired erythromelalgiaAmerican Journal of Medical Genetics, 1993